BioMarin Pharmaceutical

BioMarin inks $275M Alesta buyout to challenge AstraZeneca

Alesta is developing a small molecule to treat hypophosphatasia, a rare bone disease that is targeted by AstraZeneca’s enzyme replacement therapy, Strensiq.

Nick Paul Taylor Aug 18, 2026 9:15am

BioMarin axes $270M asset after missing phase 3 endpoint

Aug 7, 2026 9:10am

BioMarin’s $270M Inozyme rare disease bet misses key ph. 3 goal

May 18, 2026 11:05am

Helus CEO out after two months—Chutes & Ladders

Apr 24, 2026 8:30am

Midsize biotechs form coalition to fight against MFN policy

Feb 25, 2026 1:05pm

RFK Jr. continues overhaul of CDC vaccine panel—Chutes & Ladders

Jan 16, 2026 8:30am